Bishal Gyawali, MD, PhD

News

Fact vs Fallacy: Challenging the Norms of Cancer Care Fallacies in Medicine

Author:

Bishal Gyawali, MD, PhD

• Read More

News

Why Overall Survival Should Be The Oncology Trial Endpoint

Author:

Bishal Gyawali, MD, PhD

Disease progression and progression-free survival are arbitrary benchmarks that in no way imply that a patient’s subjective experience.

• Read More

Opinion

New Drug Approvals Are the Wrong Metric for Cancer Policy

Author:

Bishal Gyawali, MD, PhD

How should we define success in cancer policy — what should the endpoint be?

• Read More